Senda Biosciences

Edit info

Founded: 2016

Location: Cambridge, MA

Employee range: 50 - 200

Clinical stage: RD

Therapy area: Infectious diseases

Drug types: INF, ONC, IMM, GEN

Lead product: Undisclosed

Funding: $123M C Aug 2022; $98M B Jun 2021

Investors: Flagship Pioneering, Samsung Life Science Fund, Qatar Investment Authority, Bluwave Capital and Stage 1 Ventures, Alexandria Venture Investments, Longevity Vision Fund, Mayo Clinic, Partners Investment, State of Michigan Retirement System

sendabiosciences.com

linkedin.com

job board

Drug notes:

Undisclosed programs RD immuno-oncology, metabolic conditions, autoimmune conditions, genetic diseases

About:

Senda Biosciences is pursuing ‘intersystems’ biology to develop medicines. A grand vision in biology is to be able to program any cell in vivo, anywhere in the body, for any function. While many companies are developing methods to program _within the cell_, Senda is also trying to program _to the cell_. Programming to the cell involves understanding the molecule exchange between human and non-human cells that transfer information. Senda is using its ‘Senda Atlas’ platform to deconstruct nature’s code to program “information molecules” and natural nanoparticles with desired bioproperties. Information molecules include mRNA (SendRNA) , DNA, siRNA and gene editors and will enable Senda to target a wide range of currently unreachable cells and tissues in the body.